Relapsing Forms of Multiple Sclerosis Clinical Trial
Official title:
Time and Motion Study for Ocrelizumab and Ofatumumab Administration in Relapsing Multiple Sclerosis
This is an observational cross-sectional study of Ocrelizumab or Ofatumumab administrations for Relapsing forms of Multiple Sclerosis (RMS) in selected sites in the US, the UK and Australia.
Patients with RMS receiving Ocrelizumab or Ofatumumab will be recruited to measure the time spend for Healthcare Providers (HCP) (neurologist, nurse and hospital pharmacist) on preparing, administering the medication and following up with the patient. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01201356 -
Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis
|
Phase 3 | |
| Suspended |
NCT04909502 -
Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Relapsing Forms of Multiple Sclerosis
|
Phase 2 | |
| Recruiting |
NCT05083923 -
A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS)
|
Phase 3 | |
| Completed |
NCT02230969 -
Plegridy Observational Program
|
||
| Withdrawn |
NCT02428218 -
Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
|
Phase 3 | |
| Completed |
NCT01873417 -
Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States
|
Phase 4 | |
| Recruiting |
NCT05798520 -
A Study to Evaluate Safety and Efficacy of BIIB091 in Participants With Relapsing Forms of Multiple Sclerosis
|
Phase 2 | |
| Completed |
NCT00424788 -
A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS)
|
Phase 0 | |
| Recruiting |
NCT06251986 -
A Cross-sectional Study to Assess the Effectiveness and Safety of Ofatumumab (Kesimpta®) in Patients With Relapsing Multiple Sclerosis in the Spanish Clinical Practice
|
||
| Completed |
NCT02097849 -
Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.
|
Phase 2 | |
| Completed |
NCT01903291 -
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
|
N/A | |
| Completed |
NCT01216072 -
A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis
|
Phase 4 |